Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Truist Securities has reaffirmed its Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA), raising the price target from $17.00 to $26.00. This adjustment reflects a potential 48.66% increase from the current share price of $17.49. Iovance Biotherapeutics, a clinical-stage biopharmaceutical company, is focused on developing personalized T-cell therapies for solid tumor cancers and is preparing for potential U.S. regulatory approvals.
March 07, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Iovance Biotherapeutics, raising the price target to $26, indicating a potential 48.66% upside from the current price.
The reaffirmation of the Buy rating and the significant increase in the price target by Truist Securities are strong indicators of confidence in Iovance Biotherapeutics' potential, especially as it advances its personalized T-cell therapies for cancer. This analyst endorsement could positively influence investor sentiment and drive short-term price movement upwards.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100